<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03555422</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-024</org_study_id>
    <secondary_id>ENGOT-EN5</secondary_id>
    <secondary_id>BGOG-EN5</secondary_id>
    <secondary_id>2017-000607-25</secondary_id>
    <nct_id>NCT03555422</nct_id>
  </id_info>
  <brief_title>Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]</brief_title>
  <acronym>ENGOT-EN5</acronym>
  <official_title>A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BGOG - Belgium and Luxembourg Gynaecological Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NOGGO - North-Eastern German Society of Gynaecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MITO - Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GEICO - Spanish Research Group in Ovarian Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CEEGOG - Central and Eastern European Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ISGO - Israel Society of Gynecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, double-blind, placebo-controlled, randomized Phase 3
      study. The purpose of the study is to obtain evidence of efficacy for maintenance selinexor
      in participants with advanced or recurrent endometrial cancer. Participants with primary
      stage IV or recurrent disease who are in partial or complete response after having completed
      a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized in a
      2:1 manner to maintenance therapy with 80 milligram (mg) with selinexor once weekly (QW) or
      placebo until progression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind placebo controlled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Time from randomization until disease progression (PD) or death, whichever occurs first (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Compare progression free survival of the two treatment arms as assessed by the investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival: Assessed by Blinded Independent Central Review (BICR), per RECIST v1.1</measure>
    <time_frame>Time from randomization until PD or death, whichever occurs first (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Time from randomization until documented PD or death due to any cause, whichever occurs first. Documented PD will be based on BICR assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Specific Survival (DSS)</measure>
    <time_frame>Time from randomization until death from endometrial cancer (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Time from randomization until date of death from endometrial cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Time from randomization until death (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Time from randomization until date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Subsequent Treatment (TFST)</measure>
    <time_frame>Time from randomization until first therapy initiation after discontinuation of study drug or death, whichever occurs first (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Time from randomization until date of initiation of first therapy after discontinuation of study drug or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival After Subsequent Treatment (PFS2)</measure>
    <time_frame>Time from randomization until second documented PD or death (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Time from randomization until the second documented disease progression or death due to any cause by any cause on any subsequent line of anticancer therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Second Subsequent Treatment (TSST)</measure>
    <time_frame>Time from randomization until second therapy initiation after discontinuation of study drug or death, whichever occurs first (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Time from randomization until date of initiation of second therapy after discontinuation of study drug or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Time from randomization up to approximately 16 weeks</time_frame>
    <description>Best response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) among patients with PR as best response to prior chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HR-QoL): Measured by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30</measure>
    <time_frame>Every 12 weeks during study period, at PD and post PD at 3 and 6 months (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Patient-reported outcomes will be measured by the EORTC QLQ C30 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life: Measured by EORTC QLQ-EN24</measure>
    <time_frame>Every 12 weeks during study period, at PD and post PD at 3 and 6 months (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Patient-reported outcomes will be measured by the EORTC QLQ-EN24 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life: Measured by EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)</measure>
    <time_frame>Every 12 weeks during study period, at PD and post PD at 3 and 6 months (approximately 12 months after the last participant enrolled)</time_frame>
    <description>Patient-reported outcomes will be measured by the EORTC EQ-5D-5L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events (TEAEs), Occurrence, Nature, and Severity of AEs</measure>
    <time_frame>From first drug administration up to 30 days after last dose (approximately 12 months after the last patient enrolled)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Significant Physical Examination, Clinical Laboratory, and Vital Signs Results</measure>
    <time_frame>From first drug administration up to 30 days after last dose (approximately 12 months after the last patient enrolled)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Selinexor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive fixed dose of selinexor 80 mg (or 60 mg for participants with a body mass index [BMI] less than [&lt;] 20 kilogram per meter square [kg/m^2]) oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo for selinexor</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo for selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral</description>
    <arm_group_label>Selinexor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo for selinexor</intervention_name>
    <description>Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral</description>
    <arm_group_label>Matching placebo for selinexor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, at least 18 years of age at the time of informed consent.

          -  Histological confirmed endometrial cancer of the endometrioid, serous, or
             undifferentiated type. Carcinosarcoma of the uterus is also allowed.

          -  Completed a single line of at least 12 weeks of taxane-platinum combination therapy
             (not including adjuvant or neoadjuvant therapy), and achieved partial remission (PR)
             or complete remission (CR) according to RECIST version 1.1 for:

          -  Primary Stage IV disease, defined as:

          -  had a primary or later debulking surgery during first-line taxane-platinum therapy
             with R0 resection (R0 resection indicates a macroscopic complete resection of all
             visible tumor) and achieved CR after at least 12 weeks taxane-platinum chemotherapy,
             OR

          -  had a primary or later debulking surgery during first-line taxane-platinum therapy
             with R1 resection (R1 resection indicates incomplete removal of all macroscopic
             disease,) and achieved PR or CR after at least 12 weeks taxane-platinum chemotherapy,
             OR

          -  had no surgery and achieved PR or CR after at least 12 weeks
             taxane-platinumchemotherapy.

        OR

          -  At first relapse (i.e., relapse after primary therapy including surgery and/or
             chemotherapy therapy for Stage I-IV disease), defined as:

          -  had Stage I-III disease at diagnosis and received at initial diagnosis adjuvant
             chemotherapy and relapsed later. Participants should have PR or CR after at least 12
             weeks of taxane-platinum chemotherapy compared with the start of this chemotherapy at
             the time of relapse, OR

          -  had Stage I-III disease at diagnosis and did not receive adjuvant chemotherapy at
             initial diagnosis and relapsed later. Participants should have PR or CR after at least
             12 weeks of taxane-platinum chemotherapy compared with the start of this chemotherapy
             at the time of relapse, OR

          -  had Stage IV disease at diagnosis and received initially chemotherapy with or without
             surgery and relapsed later. At the time of relapse, participants should have PR or CR
             after at least 12 weeks of taxane-platinum chemotherapy compared with the start of
             this chemotherapy at the time of relapse.

        Participants that required their chemotherapy dose held during the 12-week therapy may be
        considered if they meet the other criteria above and achieve PR or CR per RECIST V1.1.

          -  Must be able to initiate study drug 5 to 8 weeks after completion of their final dose
             of chemotherapy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

          -  Participants must have adequate bone marrow function and organ function within 2 weeks
             before starting study drug as defined by the following laboratory criteria:

          -  Hepatic function: total bilirubin up to 1.5*upper limit of normal (ULN); alanine
             aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to (≤)
             2.5*ULN in participants without liver metastasis. For participants with known liver
             involvement of their tumor: AST and ALT ≤5*ULN.

          -  Hematopoetic function: Absolute neutrophil count (ANC) greater than or equal to (≥)
             1.5*10^9/L; platelet count ≥100*10^9 per liter (/L); hemoglobin ≥9.0 gram per
             deciliter (g/dL).

          -  Renal function: estimated creatinine clearance (CrCl) of ≥20 milliliter per minute
             (mL/min), calculated using the Cockroft Gault formula.

          -  In the opinion of the Investigator, the participant must:

          -  Have a life expectancy of at least 12 weeks, and

          -  Be fit to receive experimental therapy.

          -  Premenopausal females of childbearing potential must have a negative pregnancy test
             (serum β-human chorionic gonadotropin test) prior to the first dose of study drug.
             Female participants of childbearing potential must agree to use highly effective
             methods of contraception throughout the study and for 1 week following the last dose
             of study drug.

          -  Written informed consent in accordance with federal, local, and institutional
             guidelines. The participant must provide informed consent prior to the first Screening
             procedure.

        Exclusion Criteria:

          -  Has any sarcomas, small cell carcinoma with neuroendocrine differentiation, or clear
             cell carcinomas.

          -  Received a blood or platelet transfusion during 4 weeks prior to randomization.

          -  Being treated with a concurrent cancer therapy.

          -  Previous treatment with an exportin 1 (XPO1) inhibitor.

          -  Previous treatment with anti- programmed cell death protein 1 (PD-1) or
             anti-programmed cell death ligand-1 (PD-L1) immunotherapy (e.g., pembrolizumab).

          -  Concurrent treatment with an investigational agent or participation in another
             clinical trial.

          -  Participants who received any systemic anticancer therapy including investigational
             agents or radiation ≤3 weeks (or ≤5 half-lives of the drug [whichever is shorter])
             prior to cycle 1 day 1 (C1D1). Palliative radiotherapy may be permitted for
             symptomatic control of pain from bone metastases in extremities, provided that the
             radiotherapy does not involve target lesions, and the reason for the radiotherapy does
             not reflect progressive disease (PD).

          -  Major injuries or surgery within 14 days prior to C1D1 and/or planned surgery during
             the on-treatment study period.

          -  Previous malignant disease, except participants with other malignant disease, for
             which the participant has been disease-free for at least 3 years. Concurrent other
             malignant disease except for curatively treated carcinoma in situ of the cervix or
             basal cell carcinoma of the skin.

          -  Any life-threatening illness, medical condition or organ system dysfunction, which, in
             the investigator's opinion, could compromise the participant's safety or compliance
             with the protocol.

          -  Known contraindications to selinexor.

          -  Known uncontrolled hypersensitivity to the investigational drug, or to its excipients.

          -  Radiotherapy to the target lesion within the past 3 months prior to baseline imaging.

          -  Persistent Grade 3 or 4 toxicity from previous chemotherapy and/or radiotherapy, with
             the exception of alopecia.

          -  Active brain metastases (e.g., stable for &lt;8 weeks, no adequate previous treatment
             with radiotherapy and/or surgery, symptomatic, requiring treatment with
             anti-convulsants. Corticoid therapy is allowed if administered as stable dose for at
             least 1 month before randomization).

          -  Known unstable cardiovascular function:

          -  Symptomatic ischemia, or

          -  Uncontrolled clinically significant conduction abnormalities (i.e., ventricular
             tachycardia on anti-arrhythmia are excluded; 1st degree atrioventricular block or
             asymptomatic left anterior fascicular block /right bundle branch block will not be
             excluded), or

          -  Congestive heart failure of New York Heart Association Class ≥3, or

          -  Myocardial infarction within 3 months

          -  Females who are pregnant or actively breastfeeding.

          -  Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics,
             antivirals, or antifungals within 1 week prior to first dose; however, prophylactic
             use of these agents is acceptable even if parenteral.

          -  Active hepatitis C and/or B infection.

          -  Participants unable to swallow tablets, participants with malabsorption syndrome, or
             any other gastrointestinal (GI) disease or GI dysfunction that could interfere with
             absorption of study drug. A history of bowel obstruction requiring a nasogastric tube
             or intravenous infusion during the past 2 months is not allowed (except when this
             obstruction is caused by surgery or other non-malignant causes).

          -  Psychiatric illness or substance use that would prevent the participant from giving
             informed consent or being compliant with the study procedures.

          -  Participants unwilling or unable to comply with the protocol.

          -  Persons who have been committed to an institution by official or judicial order.

          -  Participants with dependency on the Sponsor, Investigator or study site.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jatin Shah Executive Vice President and Chief Medical Officer, MD</last_name>
    <phone>(617) 658-0600</phone>
    <email>jshah@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham President and Chief Scientific Officer, PhD</last_name>
    <phone>(617) 658-0600</phone>
    <email>sshacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Oncology</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Klinker</last_name>
      <phone>520-269-3821</phone>
      <email>julie.klinker@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Buscema</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renjini Blakrishnan</last_name>
      <phone>650-723-0594</phone>
      <email>balakrishnan9@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Berek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazmin Rodriguez</last_name>
      <phone>813-745-4673</phone>
      <email>Yazmin.Rodriguez@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Hye Sook Chon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists (Sarah Cannon Research Institute)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Shaw</last_name>
      <phone>615-524-4016</phone>
      <email>colleen.shaw@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Spitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Cuvo</last_name>
      <phone>404-236-8304</phone>
      <email>jennifer.cuvo@northside.com</email>
    </contact>
    <investigator>
      <last_name>Meaghan Tenney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covenant HealthCare</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Wasmiller</last_name>
      <phone>989-583-6494</phone>
      <email>swasmiller@chs-mi.com</email>
    </contact>
    <investigator>
      <last_name>Gregory Sutton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Health - Kansas City (Sarah Cannon Research Institute)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla McNutt</last_name>
    </contact>
    <contact_backup>
      <phone>816-276-9698</phone>
      <email>Karla.McNutt@hcamidwest.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kristopher LyBarger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Li</last_name>
      <phone>646-735-8278</phone>
      <email>Lik2@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Vicky Makker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee Sun Kim-Suh</last_name>
      <phone>405-271-8777</phone>
      <email>HeeSun-Kim@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Debra Richardson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology Nashville (Sarah Cannon Research Institute)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Shaw</last_name>
      <phone>615-524-4016</phone>
      <email>colleen.shaw@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Erika Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Kyle</last_name>
      <phone>214-648-7094</phone>
      <email>Kelly.Kyle@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>David Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen K.U. Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge Lefever</last_name>
      <phone>3216347680</phone>
      <email>inge.lefever@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Ignace Vergote, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jan Yperman Ziekenhuis</name>
      <address>
        <city>Ieper</city>
        <zip>8900</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marijke Ghekiere</last_name>
      <phone>003257357300</phone>
      <email>marijke.ghekiere@yperman.net</email>
    </contact>
    <investigator>
      <last_name>Debbie Debaere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Pare</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Blockmans</last_name>
      <phone>003265417510</phone>
      <email>marianne.blockmans@hap.be</email>
    </contact>
    <investigator>
      <last_name>Nathalie Cornez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Geentjens</last_name>
      <phone>003214406912</phone>
      <email>sarah.geentjens@azturnhout.be</email>
    </contact>
    <investigator>
      <last_name>Isabelle Cadron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta; Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Usha Kumar</last_name>
      <phone>780-989-8169</phone>
      <email>CCISite.Selection@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Kolinsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre (London Regional Cancer Centre)</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Moore</last_name>
      <phone>519-685-8618</phone>
      <email>patricia.moore@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Stephen Welch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network (PMCC)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandra Yosifova</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>3692</phone_ext>
      <email>Aleksandra.Yosifova@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Amit Oza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre (MUHC)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Vigneault</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>31975</phone_ext>
      <email>taylor.grant@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Lucy Gilbert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite Berlin Universitatsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Maria Mira-Conti</last_name>
      <phone>493 086800 1402</phone>
      <email>anna-maria.mira-conti@charite.de</email>
    </contact>
    <investigator>
      <last_name>Jalid Sehouli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagit Stolz</last_name>
      <phone>972-52-6377061</phone>
      <email>hagitst@hy.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ilan Bruchim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gali Bortnik</last_name>
      <phone>972-3-5028408</phone>
      <email>scurology@wolfson.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Tally Levy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yair Plesser</last_name>
      <phone>972-2-6555727</phone>
      <email>yairp@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Ora Rosengarten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat -Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hila Sabag</last_name>
      <phone>972-50-7649502</phone>
      <email>vera.leibo@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Tamar Perri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagit Damchiner</last_name>
      <phone>972-3-697615</phone>
      <email>hagitdp@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Tamar Safra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Candiolo, FPO, IRCCS</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cosimo Martino</last_name>
      <phone>0039 0119933842</phone>
      <email>cosimo.martino@ircc.it</email>
    </contact>
    <investigator>
      <last_name>Giorgio Valabrega</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Romagnolo Scientific Institute for the Study and Treatment of Tumors</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgia Ravaglia</last_name>
      <phone>0039 0543731075</phone>
      <email>giorgia.ravaglia@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Ugo de Giorgi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgia Lupi</last_name>
      <phone>00393381027156</phone>
      <email>lupi.giorgia@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Giorgia Mangili</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ULSS 3 SERENISSIMA UOC Oncologia Ed Ematologia Oncologica</name>
      <address>
        <city>Mirano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Coccato</last_name>
      <phone>0039 041 5794433</phone>
      <email>silvia.coccato@aulss3.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Grazia Artioli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS &quot;Fondazione G. Pascale&quot; - NAPOLI</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margherita Tambaro</last_name>
      <phone>0039 0815903637</phone>
      <email>m.tambaro@istitutotumori.na.it</email>
    </contact>
    <investigator>
      <last_name>Carmela Pisano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Agostino Gemelli University Polyclinic Foundation</name>
      <address>
        <city>Rome</city>
        <zip>30161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michela Panella</last_name>
      <phone>0039 063015 8545</phone>
      <email>michela.panella@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Scambia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>San Sebastián</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Díez</last_name>
      <phone>34 943 00 60 32</phone>
      <email>maria.diez@biodonostia.org</email>
    </contact>
    <investigator>
      <last_name>Nera Ancizar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d' Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meritxell Soler</last_name>
      <phone>34 93 274 6000</phone>
      <email>msoler@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Ana Oaknin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Berengue</last_name>
      <phone>+34 93.227.54.00 ext 2811</phone>
      <phone_ext>2811</phone_ext>
      <email>BERENGUE@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Lydia Gaba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Barcelona</city>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carme Aracil</last_name>
      <phone>34 93-700-36-12</phone>
      <email>caracil@cst.cat</email>
    </contact>
    <investigator>
      <last_name>Angels Arcusa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Arévalo</last_name>
      <phone>34 91 336 82 63</phone>
      <email>anamaria.arevalo@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Eva Guerra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berenice Brihuega Arribas</last_name>
      <phone>0034 911917418</phone>
      <email>bbrihuega@idiphim.org</email>
    </contact>
    <investigator>
      <last_name>Constanza Maximiano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofía</name>
      <address>
        <city>Madrid</city>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Perez</last_name>
      <email>lperez_ec@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Cesar Gomez-Raposo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Ruiz Carreño</last_name>
      <phone>+34 968 36 93 87</phone>
      <email>dm.oncoarrixaca@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jeronimo Martinez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Palma</city>
        <zip>071998</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabina Soler Duran</last_name>
      <phone>34 871202000</phone>
      <email>ssoler@hsll.es</email>
    </contact>
    <investigator>
      <last_name>Maria Iglesias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Rodríguez</last_name>
      <phone>34 955013068</phone>
      <email>econcologia.huvr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Purificacion Estevez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Mallol</last_name>
      <phone>34 961104606</phone>
      <email>coordinacion@fincivo.org</email>
    </contact>
    <investigator>
      <last_name>Ignacio Romero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Castelló</last_name>
      <phone>0034 961973527</phone>
      <email>ecastello@incliva.es</email>
    </contact>
    <investigator>
      <last_name>Jose Alejandro Perez-Fidalgo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico de La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian Lavin</last_name>
      <phone>34 961244188</phone>
      <email>ckm.nival@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Santaballa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Huércanos</last_name>
      <phone>+34 976 76 57 69</phone>
      <email>ihuercanos@iisaragon.es</email>
    </contact>
    <investigator>
      <last_name>Alfonso Yubero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrial Neoplasms</keyword>
  <keyword>Uterine Neoplasms</keyword>
  <keyword>Genital Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Uterine Diseases</keyword>
  <keyword>Genital Diseases</keyword>
  <keyword>Female</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

